Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs. Avanafil, from 50 to 200 mg, is effective and well tolerated for the treatment of ED from 50 to 200 mg, and an increase in dosage is associated with a significant rise in effectiveness but not with more adverse events significantly.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 80 mg/mL|
The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis.
Wang H, et al. Curr Med Res Opin. 2014 Apr 14. PMID: 24701971.
|Related PDE Products|
Vesnarinone is a cardiotonic agent, mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity.
Roflumilast N-oxide is a phosphodiesterase 4 inhibitor.
CP671305 is a potent and selective, orally active inhibitor of phosphodiesterase-4-D with high activities.
ITI-214 phosphate is an orally active, potent and selective inhibitors of PDE1, exhibits potent PDE1 inhibitory activity (Ki = 58 pM).
IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.